Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Received Consensus Recommendation to “Hold” by Brokerages

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN- Get a rating) received an average recommendation of “Hold” from the nine rating agencies that cover the company, reports Marketbeat Ratings. Six analysts rated the stock with a hold recommendation and two gave the company a buy recommendation. The 1-year average price target among analysts who have reported on the stock in the past year is $153.93.

Several research companies have recently published reports on BHVN. Wedbush downgraded shares of Biohaven Pharmaceutical from an “outperform” rating to a “neutral” rating and set a price target of $148.50 for the stock. in a research report on Monday, August 8. Piper Sandler downgraded shares of Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating and set a price target of $149.00 for the company. in a research note on Thursday, August 18.

Insider activity

In other Biohaven Pharmaceutical news, Director Gregory Bailey purchased 38,000 shares of the company in a trade dated Friday, August 19. The shares were purchased at an average price of $148.04 per share, with a total value of $5,625,520.00. Following the completion of the purchase, the director now owns 2,583,658 shares of the company, valued at $382,484,730.32. The transaction was disclosed in an SEC filing, available at the SEC website. Insiders hold 12.40% of the shares of the company.

Hedge funds weigh on Biohaven Pharmaceutical

A d x1esports

Get your in-game wallet today!

This games and media holding company brings a unique consolidation strategy and a diverse mix of experiences brought by its management team to a changing and highly fragmented space.

Several large investors have recently changed their holdings in BHVN. Park Avenue Securities LLC increased its stake in Biohaven Pharmaceutical by 24.9% during the first quarter. Park Avenue Securities LLC now owns 2,122 shares of the company worth $252,000 after purchasing 423 additional shares in the last quarter. Gyroscope Capital Management Group LLC bought a new position in Biohaven Pharmaceutical during the first quarter at a value of $2,371,000. Sigma Planning Corp increased its stake in Biohaven Pharmaceutical by 6.3% during the first quarter. Sigma Planning Corp now owns 6,486 shares of the company worth $769,000 after buying 386 more shares in the last quarter. Myriad Asset Management Ltd. acquired a new position in Biohaven Pharmaceutical during the fourth quarter with a value of $1,984,000. Finally, ACT Capital Management LLC bought a new position in Biohaven Pharmaceutical during the first quarter at a value of $249,000. Institutional investors hold 78.19% of the company’s shares.

Biohaven Pharmaceutical trades up 0.5%

NYSE BHVN opened at $150.92 on Friday. The company has a market capitalization of $10.80 billion, a price-earnings ratio of -10.18 and a beta of 1.04. The company’s 50-day simple moving average is $147.17 and its 200-day simple moving average is $133.01. Biohaven Pharmaceutical has a 1-year low of $79.01 and a 1-year high of $151.51.

Biohaven Pharmaceutical (NYSE: BHVN – Get a rating) last released its quarterly results on Friday, August 5. The company reported ($6.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.79) by ($3.42). The company posted revenue of $215.08 million for the quarter, versus analyst estimates of $209.33 million. On average, stock research analysts expect Biohaven Pharmaceutical to post -12.71 earnings per share for the current year.

Biohaven Pharmaceutical Company Profile

(Get a rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Featured Articles

Analyst Recommendations for Biohaven Pharmaceutical (NYSE: BHVN)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Biohaven Pharmaceutical, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.

While Biohaven Pharmaceutical currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here